# Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

> **NCT05218759** · NA · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT05218759
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-21
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218759, "Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05218759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*